Is Recursion Pharmaceuticals, Inc. (RXRX) a Buy, Sell, or Hold?
Recursion Pharmaceuticals, Inc.
NASDAQ:RXRX
$3.406 USD
$0.07 (1.98%)
- Volume
- 4.25M
- Average Volume
- 19.03M
- Market Capitalization
- $1.52B
- P/E Ratio
- -2.84
- Dividend Yield
- 0.00%
- Price Target
- $5.50
- Year High
- $7.18
- Year Low
- $2.77
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.47
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Najat Khan |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | RXRX |
| CUSIP | 75629V104 |
| CIK | 0001601830 |
| Web | https://www.recursion.com |
| Phone | 385 269 0203 |
| Currency | USD |
| Employees | 600 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.07 |
| Payout Ratio | 0.00 |
| Current Ratio | 5.47 |
| Quick Ratio | 5.47 |
| Cash Ratio | 5.05 |
Sales & Book Value
| Annual Sales | $74.68M |
| Price / Sales | 22.98 |
| Cash Flow | -0.62 |
| Price / Cash Flow | -4.67 |
| Price / Book | 1.76 |
Price Target and Rating
| Average Stock Price Forecast | $5.50 |
| High Stock Price Forecast | $5.50 |
| Low Stock Price Forecast | $5.50 |
| Forecast Upside/Downside | -38.07% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 10 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.44 |
| Trailing P/E Ratio | -2.84 |
| PEG Ratio | -0.08 |
| P/E Growth | -0.08 |
| Net Income | $-644.76M |
| Net Margin | -844.46% |
| Pretax Margin | -851.37% |
| Return on Equity | -54.32% |
| Return on Assets | -41.79% |
Financials Score
| AltmanZ Score | -0.28 |
| Piotroski Score | 3.00 |
| Working Capital | 579.86M |
| Total Assets | 1.34B |
| Ebit | -563.53M |
| Market Cap | 1.49B |
| Total Liabilities | 314.75M |
Poll Results
About Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium diffici ... le colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today
2026-07-14 18:51:13
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.34, indicating a +1.21% shift from the previous trading day.
2 Beaten-Down Stocks That Still Aren't Worth Buying
2026-07-11 16:30:00
Recursion Pharmaceuticals has yet to prove that its approach to developing medicines is superior. Sarepta Therapeutics will struggle to shake off safety concerns about its most important therapy.
Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Market
2026-07-08 18:51:07
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.72, moving 3.13% from the previous trading session.
3 Cancer Stocks to Watch as Oncology Innovation Accelerates
2026-07-08 09:35:14
Oncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeline growth and spotlight promising cancer-focused stocks.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
2026-07-05 06:03:00
Two stocks that have fallen out of favor and one hot stock that was one of Thursday's biggest losers were on the Ark Invest founder's shopping list.
2026-07-04 09:21:09
Dyne Therapeutics is advancing a clinical-stage platform specifically targeting genetically driven neuromuscular diseases. Recursion Pharmaceuticals utilizes an artificial intelligence OS to accelerate drug discovery across several therapeutic areas.
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?
2026-07-03 11:14:15
Moderna is evolving from a COVID-19 vaccine specialist into a multi-product firm with major oncology and rare disease partnerships. Recursion Pharmaceuticals is leveraging artificial intelligence and massive biological datasets to accelerate drug discovery via high-tech collaborations.
AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity
2026-06-30 09:38:29
Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from Silicon Valley. Biotechnology has spent decades producing breakthrough medicines, yet drug development has remained painfully slow, often taking 10 to 15 years while roughly 90% of candidates never reach approval. AI is beginning to change that equation. By... AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity
Frequently Asked Questions
-
What is the current Recursion Pharmaceuticals, Inc. (RXRX) stock price?
-
Recursion Pharmaceuticals, Inc.(NASDAQ:RXRX) stock price is $3.406 in the last trading session. During the trading session, RXRX stock reached the peak price of $7.18 while $2.77 was the lowest point it dropped to. The percentage change in RXRX stock occurred in the recent session was 1.98% while the dollar amount for the price change in RXRX stock was $0.07.
-
RXRX's industry and sector of operation?
-
The NASDAQ listed RXRX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of RXRX?
-
Vicki L. Goodman | Chief Medical Officer
Benjamin Mabey | Chief Technology Officer
Sid Jain | Senior Vice President of Clinical Development & Data Science
Erica Fox | Chief People and Impact Officer
Kristen Rushton | Chief Operating Officer -
How many employees does RXRX have?
-
Number of RXRX employees currently stands at 600. RXRX operates from 41 South Rio Grande Street, Salt Lake City, UT 84101, US.
-
Link for RXRX official website?
-
Official Website of RXRX is: https://www.recursion.com
-
How do I contact RXRX?
-
RXRX could be contacted at phone #385 269 0203 and can also be accessed through its website. RXRX operates from 41 South Rio Grande Street, Salt Lake City, UT 84101, US.
-
How many shares of RXRX are traded daily?
-
The average number of RXRX shares traded daily for last 3 months was 19.03M.
-
What is the market cap of RXRX currently?
-
The market value of RXRX currently stands at $1.52B with its latest stock price at $3.406